Any feedback?
Information on EC 2.6.1.52 - phosphoserine transaminase
for references in articles please use BRENDA:EC2.6.1.52Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.6.1.52 phosphoserine transaminaseIUBMB Comments
A pyridoxal 5'-phosphate protein. This enzyme catalyses the second step in the phosphorylated pathway of serine biosynthesis [1,3] and the third step in pyridoxal 5'-phosphate biosynthesis in the bacterium Escherichia coli . Pyridoxal 5'-phosphate is the cofactor for both activities and therefore seems to be involved in its own biosynthesis . Non-phosphorylated forms of serine and threonine are not substrates . The archaeal enzyme has a relaxed specificity and can act on L-cysteate and L-alanine as alternative substrates to O-phospho-L-serine .
Specify your search results
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Synonyms
psat, phosphoserine aminotransferase, phosphoserine aminotransferase 1, ehpsat, 3-phosphoserine aminotransferase, psat2, l-phosphoserine aminotransferase, psat beta, bmpsat, psat alpha, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
3-phosphoserine aminotransferase
-
-
-
-
AspAT
bmPSAT
EhPSAT
hydroxypyruvic phosphate-glutamic transaminase
-
-
-
-
L-phosphoserine aminotransferase
-
-
-
-
phosphohydroxypyruvate transaminase
-
-
-
-
phosphohydroxypyruvic-glutamic transaminase
-
-
-
-
phosphoserine aminotransferase
phosphoserine aminotransferase 1
phosphoserine aminotransferases
PSAT
PSAT1
serC
phosphoserine aminotransferase
-
-
-
-
PSAT
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
4-phosphooxy-L-threonine + 2-oxoglutarate = (3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
(2)
-
-
-
O-phospho-L-serine + 2-oxoglutarate = 3-phosphooxypyruvate + L-glutamate
A pyridoxal-phosphate protein
-
-
-
O-phospho-L-serine + 2-oxoglutarate = 3-phosphooxypyruvate + L-glutamate
mechanism of pyridoxal 5-phosphate activation, X-ray analysis of lysine-pyridoxal 5-phosphate Schiff base
-
O-phospho-L-serine + 2-oxoglutarate = 3-phosphooxypyruvate + L-glutamate
bimolecular ping-pong mechanism, the transamination reaction catalyzed by PSAT consists of two reversible half-reactions, detailed overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
amino group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
KEGG
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
O-phospho-L-serine:2-oxoglutarate aminotransferase
A pyridoxal 5'-phosphate protein. This enzyme catalyses the second step in the phosphorylated pathway of serine biosynthesis [1,3] and the third step in pyridoxal 5'-phosphate biosynthesis in the bacterium Escherichia coli [3]. Pyridoxal 5'-phosphate is the cofactor for both activities and therefore seems to be involved in its own biosynthesis [4]. Non-phosphorylated forms of serine and threonine are not substrates [4]. The archaeal enzyme has a relaxed specificity and can act on L-cysteate and L-alanine as alternative substrates to O-phospho-L-serine [7].
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9030-90-4
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
2-amino-4-phosphonobutyrate + 2-oxoglutarate
2-oxophosphonobutanoate + L-glutamate
-
-
-
-
r
2-amino-5-phosphonovalerate + 2-oxoglutarate
5-phosphono-2-oxopentanoate + L-glutamate
-
-
-
-
r
2-oxo-3-hydroxy-4-phosphobutanoate + L-glutamate
4-(phosphonooxy)-L-threonine + 2-oxoglutarate
-
2-oxo-3-hydroxy-4-phosphobutanoate = 3-hydroxy-4-O-phosphoryl-2-oxobutyrate
4-phospho-hydroxy-L-threonine = 4-O-phosphoryl-L-threonine
-
?
4-phosphooxy-L-threonine + 2-oxoglutarate
(3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
L-glutamate + 4,5-dioxopentanoate
5-aminolevulinate + 2-oxoglutarate
-
-
-
-
?
3-phosphonooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
?
3-phosphonooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
?
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
4-phosphooxy-L-threonine + 2-oxoglutarate
(3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
-
-
-
r
4-phosphooxy-L-threonine + 2-oxoglutarate
(3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
-
-
-
r
L-alanine + 3-phosphonooxypyruvate
O-phospho-L-serine + pyruvate
-
L-alanine as amino group donor, 10% of the activity with L-glutamate
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
phosphorylated pathway for serine biosynthesis
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
forward reaction
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
phosphorylated pathway for serine biosynthesis
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
phosphorylated pathway for serine biosynthesis
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
phosphorylated pathway for serine biosynthesis
-
-
r
L-homoserine + 2-oxoglutarate
4-hydroxy-2-oxobutyrate + L-glutamate
L-homoserine transaminase reaction of engineered enzyme mutant R42W/R77W, low activity with the wild-type enzyme
-
-
r
L-homoserine + 2-oxoglutarate
4-hydroxy-2-oxobutyrate + L-glutamate
L-homoserine transaminase reaction of engineered enzyme mutant R42W/R77W, low activity with the wild-type enzyme
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
?
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
?
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
reverse reaction
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphonooxypyruvate + L-glutamate
-
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
additional information
?
-
the transamination reaction catalyzed by PSAT consists of two reversible half-reactions, overview. Substrate binding requires a conformational change of AtPSAT1
-
-
-
additional information
?
-
-
the transamination reaction catalyzed by PSAT consists of two reversible half-reactions, overview. Substrate binding requires a conformational change of AtPSAT1
-
-
-
additional information
?
-
the enzyme preferentially utilizes glutamate for transamination
-
-
-
additional information
?
-
the enzyme preferentially utilizes glutamate for transamination
-
-
-
additional information
?
-
-
the enzyme preferentially utilizes glutamate for transamination
-
-
-
additional information
?
-
Bombyx mori b94
the enzyme preferentially utilizes glutamate for transamination
-
-
-
additional information
?
-
the enzyme preferentially utilizes glutamate for transamination
-
-
-
additional information
?
-
-
2-amino-3-phosphonopropionate, 3-amino-3-phosphonopropionate 4-amino-4-phosphonobutyrate, 1-amino-1,3-phosphonopropane, 2-amino-6-phosphohexanoate, serine, aspartate, cysteine sulfinate and cysteate are no substrates
-
-
?
additional information
?
-
-
aspartate, alanine and phosphoserine as amino donors, 2-oxoglutarate and glyoxylate as amino acceptors
-
-
?
additional information
?
-
-
aspartate, alanine and phosphoserine as amino donors, 2-oxoglutarate and glyoxylate as amino acceptors
-
-
?
additional information
?
-
-
high aspartate aminotransferase side activity
-
-
?
additional information
?
-
-
4,5-dioxovalerate with glutamate as amino donor is effective as competitive substrate to phosphohydroxypyruvate in the forward reaction and yields 5-aminolevulinate, 4,5-dioxovalerate and glutamate-1-semialdehyde can both serve as competitive aminoacceptor in the reverse reaction with phosphoserine and as substrate with 2-oxoglutarate as aminoacceptor
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
4-phosphooxy-L-threonine + 2-oxoglutarate
(3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
3-phosphooxypyruvate + L-glutamate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
4-phosphooxy-L-threonine + 2-oxoglutarate
(3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
-
-
-
r
4-phosphooxy-L-threonine + 2-oxoglutarate
(3R)-3-hydroxy-2-oxo-4-phosphooxybutanoate + L-glutamate
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
phosphorylated pathway for serine biosynthesis
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
phosphorylated pathway for serine biosynthesis
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
-
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
phosphorylated pathway for serine biosynthesis
-
-
r
L-glutamate + 3-phosphohydroxypyruvate
O-phospho-L-serine + 2-oxoglutarate
-
phosphorylated pathway for serine biosynthesis
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
O-phospho-L-serine + 2-oxoglutarate
3-phosphooxypyruvate + L-glutamate
-
-
-
r
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
pyridoxal 5'-phosphate
-
presence of cofactor influences the tertiary structure. The cofactor does not influence the secondary structure of the enzyme. Stability of the protein is significantly affected by the cofactor as holo-enzyme shows higher values for thermal and GdnHCl-induced denaturation, respectively, when compared to the apoenzyme. The cofactor also influences the unfolding pathway of the enzyme. Although urea-dependent unfolding of both holo- and apo-EhPSAT is a three-state process, the intermediates stabilized during unfolding are significantly different. For the holo-enzyme a dimeric holo-intermediate is stabilized, whereas for the apo-enzyme, a monomeric intermediate is stabilized
pyridoxal 5'-phosphate
PLP, dependent on, the PLP prosthetic group creates a Schiff base (internal aldimine) between C4' and Nzeta of K265, PLP bound in the active site forms an internal aldimine with residue K265, the residue placed in the coil between beta9 and beta10
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Aminooxyacetate
AOA, the transaminase inhibitor represses cell growth in a TAZ/YAP-dependent manner
chloride
the chloride ion in EhPSAT becomes trapped in the space between residues Gly99, Val 100, Ile 149, Thr 148, and Asn 147. The halide-binding site in close proximity to the active site is detected. A stretch of six amino acids (146-NNTIYG-151) only conserved in the Entamoeba genus, contributes to halide binding. Structure comparisons, overview
additional information
-
not inhibitory: chloride, fluoride and bromide up to 200 mM
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma of Lung
Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFN? axis.
Adenocarcinoma, Mucinous
Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers.
Breast Neoplasms
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Breast Neoplasms
Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues.
Breast Neoplasms
Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells.
Breast Neoplasms
Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis.
Breast Neoplasms
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.
Breast Neoplasms
Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer.
Carcinogenesis
Overexpression of Phosphoserine Aminotransferase 1 (PSAT1) Predicts Poor Prognosis and Associates with Tumor Progression in Human Esophageal Squamous Cell Carcinoma.
Carcinoma
MicroRNA-365 suppresses cell growth and invasion in esophageal squamous cell carcinoma by modulating phosphoserine aminotransferase 1.
Carcinoma
Overexpression of Phosphoserine Aminotransferase 1 (PSAT1) Predicts Poor Prognosis and Associates with Tumor Progression in Human Esophageal Squamous Cell Carcinoma.
Carcinoma
Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers.
Carcinoma, Non-Small-Cell Lung
Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis.
Carcinoma, Non-Small-Cell Lung
PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells.
Carcinoma, Ovarian Epithelial
PSAT1 Regulated Oxidation-Reduction Balance Affects the Growth and Prognosis of Epithelial Ovarian Cancer.
Colonic Neoplasms
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Colonic Neoplasms
Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis.
Colorectal Neoplasms
Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester.
Colorectal Neoplasms
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Contracture
Adult diagnosis of congenital serine biosynthesis defect: A treatable cause of progressive neuropathy.
Cysts
[Enhancement of resistance of mice Toxoplasma gondii by 2 polysaccharides beta 1-3, beta 1-6 (PSAT and Scleroglucan)]
Drug-Related Side Effects and Adverse Reactions
Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study.
Epilepsy
Phosphoserine aminotransferase deficiency: imaging findings in a child with congenital microcephaly.
Esophageal Neoplasms
MicroRNA-340 Inhibits Esophageal Cancer Cell Growth and Invasion by Targeting Phosphoserine Aminotransferase 1.
Esophageal Neoplasms
MicroRNA-365 suppresses cell growth and invasion in esophageal squamous cell carcinoma by modulating phosphoserine aminotransferase 1.
Esophageal Squamous Cell Carcinoma
MicroRNA-365 suppresses cell growth and invasion in esophageal squamous cell carcinoma by modulating phosphoserine aminotransferase 1.
Esophageal Squamous Cell Carcinoma
Overexpression of Phosphoserine Aminotransferase 1 (PSAT1) Predicts Poor Prognosis and Associates with Tumor Progression in Human Esophageal Squamous Cell Carcinoma.
Glioblastoma
Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.
Ichthyosis
Adult diagnosis of congenital serine biosynthesis defect: A treatable cause of progressive neuropathy.
Infections
Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study.
Infections
Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients.
Infections
[Enhancement of resistance of mice Toxoplasma gondii by 2 polysaccharides beta 1-3, beta 1-6 (PSAT and Scleroglucan)]
Insulin Resistance
Hepatic phosphoserine aminotransferase 1 (PSAT1) regulates insulin sensitivity in mice via tribbles homolog 3 (TRB3).
Lung Neoplasms
Nuclear Pyruvate Kinase M2 (PKM2) Contributes to Phosphoserine Aminotransferase 1 (PSAT1)-Mediated Cell Migration in EGFR-Activated Lung Cancer Cells.
Lung Neoplasms
Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFN? axis.
Lung Neoplasms
Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis.
Lung Neoplasms
PSAT1 regulates cyclin D1 degradation and sustains proliferation of non-small cell lung cancer cells.
Microcephaly
Phosphoserine aminotransferase deficiency: imaging findings in a child with congenital microcephaly.
Neoplasm Metastasis
Long non-coding RNA RP4-694A7.2 Promotes Hepatocellular Carcinoma Cell Proliferation and Metastasis through the Regulation of PSAT1.
Neoplasm Metastasis
Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer.
Neoplasm Metastasis
[A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups]
Neoplasms
Artemether Exhibits Amoebicidal Activity against Acanthamoeba castellanii through Inhibition of the Serine Biosynthesis Pathway.
Neoplasms
Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy.
Neoplasms
Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions.
Neoplasms
Nuclear Pyruvate Kinase M2 (PKM2) Contributes to Phosphoserine Aminotransferase 1 (PSAT1)-Mediated Cell Migration in EGFR-Activated Lung Cancer Cells.
Neoplasms
Overexpression of Phosphoserine Aminotransferase 1 (PSAT1) Predicts Poor Prognosis and Associates with Tumor Progression in Human Esophageal Squamous Cell Carcinoma.
Neoplasms
Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (gamma-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels.
Neoplasms
Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels.
Neoplasms
[Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
Neurodegenerative Diseases
Human Cerebral Cortex Proteome of Fragile X-Associated Tremor/Ataxia Syndrome.
Obesity
Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis.
Ovarian Neoplasms
Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers.
Pemphigoid, Bullous
Genetic basis of phenotypic plasticity for predator-induced morphological defenses in anuran tadpole, Rana pirica, using cDNA subtraction and microarray analysis.
phosphoserine transaminase deficiency
Adult diagnosis of congenital serine biosynthesis defect: A treatable cause of progressive neuropathy.
phosphoserine transaminase deficiency
Disturbed phospholipid metabolism in serine biosynthesis defects revealed by metabolomic profiling.
phosphoserine transaminase deficiency
Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway.
phosphoserine transaminase deficiency
Phosphoserine aminotransferase deficiency: imaging findings in a child with congenital microcephaly.